The disclosure relates to immunoglobulin variants that are useful for the design of vaccinations against a variety of athogens and their method of production and use. In some aspects, the immunoglobulin variants are variants of IgG, for example, the 6D8 antibody.

The disclosure provides an immunogenic composition comprising an haptenized Spike protein (S protein) or fragment thereof from a coronavirus and at least one pharmaceutically acceptable carrier, wherein the coronavirus comprising severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Further disclosed are methods of using the haptenized S proteins from coronavirus or immunizing a subject against coronavirus infection.

The disclosure provides an immunogenic composition comprising an haptenized Spike protein (S protein) or fragment thereof from a coronavirus and at least one pharmaceutically acceptable carrier, wherein the coronavirus comprising severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Further disclosed are methods of using the haptenized S proteins from coronavirus or immunizing a subject against coronavirus infection.

Disclosed are a non-integrative Listeria-based vaccine and a method for inducing antitumor immune response. In particular, the present disclosure provides a recombinant nucleic acid molecule, a recombinant plasmid or a recombinant expression vector comprising the recombinant nucleic acid molecule, a recombinant protein, and a recombinant Listeria. Also disclosed are a pharmaceutical composition and a vaccine comprising the above component, a method for slowly and continuously killing cells using the same, and a method for inducing immune response in a subject using the same.

Disclosed are a non-integrative Listeria-based vaccine and a method for inducing antitumor immune response. In particular, the present disclosure provides a recombinant nucleic acid molecule, a recombinant plasmid or a recombinant expression vector comprising the recombinant nucleic acid molecule, a recombinant protein, and a recombinant Listeria. Also disclosed are a pharmaceutical composition and a vaccine comprising the above component, a method for slowly and continuously killing cells using the same, and a method for inducing immune response in a subject using the same.

Outer membrane vesicles from bacteria of the Burkholderia pseudomallei complex can be used as adjuvants in compositions and methods to potentiate the immune response to immunogens.

A fusion protein comprises a first nanocage monomer subunit of a nanocage monomer; and a bioactive moiety linked to the first nanocage monomer subunit; wherein the fusion protein self-assembles with a protein comprising a second nanocage monomer subunit to form a nanocage monomer.

A fusion protein comprises a first nanocage monomer subunit of a nanocage monomer; and a bioactive moiety linked to the first nanocage monomer subunit; wherein the fusion protein self-assembles with a protein comprising a second nanocage monomer subunit to form a nanocage monomer.

Provided is a composition and method for delivery of bioactive agents to a cell or a subject. The composition includes nucleic acids derived from plants and the bioactive agents, and the nucleic acids are crossed linked by a cross-linking agent. Such composition is non-toxic, biocompatible and target specific. A method of making the composition is also provided.

Provided is a composition and method for delivery of bioactive agents to a cell or a subject. The composition includes nucleic acids derived from plants and the bioactive agents, and the nucleic acids are crossed linked by a cross-linking agent. Such composition is non-toxic, biocompatible and target specific. A method of making the composition is also provided.